搜尋結果
Vaxigrip Tetra is indicated for active immunisation of adults and children from 6 months of age and older for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine. 4.2 DOSE AND METHOD OF ADMINISTRATION .
The most frequently reported vaccine brand across all age groups (6 months−17 years, 18–64 years, and ≥65 years) was Vaxigrip Tetra. In children from 6 months to 17 years, Vaxigrip Tetra was followed by Fluenz Tetra; in adult subjects 18–64 and ≥65 years
於第二孕期及第三孕期接種。然而，從全球使用不活化流感疫苗（包括三價不活化流感疫苗Vaxigrip） 的數據來看，不活化流感疫苗對胎兒及母體並無任何不良影響。 四個臨床研究第二孕期及第三孕期的懷孕婦女接種三價不活化流感疫苗 Vaxigrip （超過 5000
AusPAR - Vaxigrip Tetra - Inactivated quadrivalent influenza vaccine (split virion) - Sanofi-Aventis Australia Pty Ltd - PM-2018-00583-1-2 FINAL 19 December 2019 Page 3 of 30
2017年11月27日 · Introduction: VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®).
Vaxigrip Tetra wird angewendet zur aktiven Immunisierung von Erwachsenen und Kindern ab. 6 Monate zur Vorbeugung einer echten Virusgrippe (Influenza), die durch die beiden Influenza-A-Virussubtypen und die beiden Influenza-B-Virussubtypen verursacht wird, gegen die der Impfstoff gerichtet ist.
2017年11月27日 · VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®).
